Publications by authors named "C Tiley"
Article Synopsis
- There is a growing interest in using historical patient data as synthetic controls for evaluating new drugs, but real-world outcomes often don't match those from clinical trials due to a lack of detailed cancer treatment data.
- The Australasian Leukaemia and Lymphoma Group's National Blood Cancer Registry (ALLG NBCR) provides comprehensive information on various factors influencing treatment outcomes, allowing for a comparison of 942 AML patients to clinical trial data for five specific drugs.
- The analysis reveals significant differences in treatment approaches and outcomes between real-world patients and clinical trial participants, indicating that while some results may align, discrepancies must be considered for accurately assessing the effectiveness of new therapies across different populations.
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk.
Cancer Epidemiol Biomarkers Prev
January 2024
Background: Epidemiologic evidence suggests an inverse association between sun exposure and follicular lymphoma risk.
Methods: We conducted an Australian population-based family case-control study based on 666 cases and 459 controls (288 related, 171 unrelated). Participants completed a lifetime residence and work calendar and recalled outdoor hours on weekdays, weekends, and holidays in the warmer and cooler months at ages 10, 20, 30, and 40 years, and clothing types worn in the warmer months.
Objectives: We aimed to examine the relationship between occupational exposure to extremely low-frequency magnetic fields (ELF-MFs) and follicular lymphoma (FL) risk.
Methods: We conducted a family case-control study between 2011 and 2016 in Australia and included 681 cases. Controls were either a family member of cases (related (n=294), unrelated (n=179)) or were unrelated recruited for a similarly designed Australian multiple myeloma study (n=711).
Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising outcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized 102 patients (aged 18-65 years) 2:1 to sorafenib vs placebo (days 4-10) combined with intensive induction: idarubicin 12 mg/m2 on days 1 to 3 plus either cytarabine 1.
View Article and Find Full Text PDF